Background: Polycystic ovary syndrome (PCOS) is an insulin-resistant state with hirsutism as a common manifestation. Objective: We hypothesized that treatment with metformin would improve the cosmetic effects of intense pulsed light (IPL) therapy for hair removal in PCOS patients. Methods: In a prospective randomized controlled trial, 70 PCOS patients randomly received metformin (1,500 mg daily) + IPL therapy or IPL therapy alone for 5 IPL sessions during a 6-month period, followed by an additional 6 months of observation. Hirsutism score, homeostasis model assessment for insulin resistance (HOMA-IR), free androgen index (FAI) and patient satisfaction were evaluated at every visit. Results: Fifty-two patients finished the study. Hirsutism was significantly better controlled in the metformin group (p = 0.009). Patient satisfaction was significantly better in the metformin group at the end of the observation period (52.9 vs. 34.1%, p = 0.019). HOMA-IR and FAI scores improved after metformin + IPL treatment (p < 0.05). Conclusion: Adding metformin to IPL in women with PCOS results in a significant improvement in insulin sensitivity and hirsutism.

Keywords:
Polycystic ovary syndrome, Metformin, Intense pulsed light, Hirsutism
1.
Harborne L, Fleming R, Lyall H, Sattar N, Norman J: Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4116–4123.
2.
Sagsoz N, Kamaci M, Orbak Z: Body hair scores and total hair diameters in healthy women in the Kirikkale region of Turkey. Yonsei Med J 2004;45:483–491.
3.
Lanigan SW: Incidence of side effects after laser hair removal. J Am Acad Dermatol 2003;49:882–886.
4.
Tanzi EL, Lupton JR, Alster TS: Lasers in dermatology: four decades of progress. J Am Acad Dermatol 2003;49:1–31.
5.
Iuorno MJ, Nestler JE: The polycystic ovary syndrome: treatment with insulin sensitizing agents. Diabetes Obes Metab 1999;1:127–136.
6.
Nestler JE: Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008;358:47–54.
7.
Kelly CJ, Gordon D: The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002;147:217–221.
8.
Chang RJ, Nakamura RM, Judd HL, Kaplan SA: Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57:356–359.
9.
Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257–1266.
10.
Baillargeon JP, Carpentier AC: Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia 2007;50:2424–2432.
11.
Starka L, Duskova M, Cermakova I, Vrbikova J, Hill M: Premature androgenic alopecia and insulin resistance: male equivalent of polycystic ovary syndrome? Endocr Regul 2005;39:127–131.
12.
Cara JF, Rosenfield RL: Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988;123:733–739.
13.
Cara JF, Fan J, Azzarello J, Rosenfield RL: Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells. J Clin Invest 1990;86:560–565.
14.
Su HY, Hickford JG, Bickerstaffe R, Palmer BR: Insulin-like growth factor 1 and hair growth. Dermatol Online J 1999;5:1.
15.
Tang L, Bernardo O, Bolduc C, Lui H, Madani S, Shapiro J: The expression of insulin-like growth factor 1 in follicular dermal papillae correlates with therapeutic efficacy of finasteride in androgenetic alopecia. J Am Acad Dermatol 2003;49:229–233.
16.
Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–89.
17.
Cheang KI, Sharma ST, Nestler JE: Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? Gynecol Endocrinol 2006;22:595–604.
18.
Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951–953.
19.
Meyer C, McGrath BP, Teede HJ: Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30:471–478.
20.
Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269–274.
21.
Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617–623.
22.
Nestler JE, Jakubowicz DJ: Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075–4079.
23.
Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–1880.
24.
Velazquez E, Acosta A, Mendoza SG: Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392–395.
25.
Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–654.
26.
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
27.
Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–1447.
28.
Horton R, Pasupuletti V, Antonipillai I: Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I. Endocrinology 1993;133:447–451.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.